The global depression drugs market was valued at $12.9 billion in 2021 and it is expected to reach $23.2 billion at a CAGR of 5.40% between 2022 and 2032. Depression drugs such as antidepressants medications can cure people who are suffering from several mental disorders. Medication is widely used in combination with antidepressant drugs such as Aplenzin, Celexa, Cymbalta, Emsam, and Elavil, among others. Moreover, an antidepressant can be helpful in depression varies from patient to patient. However, how long the depression drugs stay in a person’s body also varies. Some drugs stay 36 hours and others last as long as several days.
North America is estimated to be the leading region in the depression drugs market across the globe.
According to World Health Organization, in 2018, nearly 300 million people of all age groups suffered from mental disorders across the globe. Moreover, according to the National Institute of Mental Health, in 2017, nearly 18 million adults had suffered major depression issues in the U.S country. These increasing issues have driven the market over the last few years. Based on drug type, the market is segmented into antidepressants, serotonin-norepinephrine, reuptake inhibitors, serotonin modulators, tricyclic and tetracyclic antidepressants, atypical, antipsychotics, and others. The atypical antidepressants have dominated the market in the last two years and this trend is expected to dominate the market during the forecast period due to the increasing cases of depression and the launch of new drugs products on the global market.
Source: SAI Research
Based on disease, the depression drugs market is segmented into major depressive disorder, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and anxiety disorder, among others. Among these illnesses, schizophrenia and bipolar disorder are expected to drive the market during the forecast period. Moreover, increased cases of schizophrenia and bipolar disorder and the research on these treatments are driving this category. According to World Health Organization, bipolar disorder is expected to be the sixth-largest mental disorder across the globe.
Based on distribution channels, the global depression drugs market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies, among others. Among these, the retail pharmacies segment has dominated the market in the last two years and the trend is expected to continue during the forecast period. Based on the regions, the market is categorized into Europe, North America, Asia-Pacific, Latin America, and Africa. Among these regions, North America is dominating the global depression drugs market and it is followed by the Asia-Pacific region. The introduction of the new drug-based product to prevent various types of depression and the prevalence of mental illness in various developed countries such as the U.S, Canada, and Mexico among others are anticipated to drive the market with a significant growth rate during the forecast period from 2022 to 2032.
Key players such as Johnson and Johnson Company (U.S), Merck Pharmaceutical Company (U.S), GlaxoSmithKline Pharmaceutical Company (U.K), Sanofi Pharmaceutical Company (France), Pfizer Pharmaceutical Company (U.S), AstraZeneca Pharmaceutical Industry Company (U.K), Alkermes Biotechnology Company (Ireland), among others are leading the depression drugs market across the globe.
Scope of the Report:
Report Coverage |
Details |
||
Base Year: |
2021 |
Market Size in 2021: |
US$ 12.9 Billion |
Historical Data for: |
2019, 2020 and 2021 |
Forecast Period: |
2022 to 2032 |
Forecast Period 2022 to 2032 CAGR: |
23.2% |
2032 Value Projection: |
US$ 5.40 Billion |
Segments covered: |
By Drug Type: Antipsychotics, Antidepressants, and Generic Drugs, Branded Drugs & Others. By Distributional Channel: Hospital, Retail Stores, Online Pharmacies & Other By Mental Disorder Type: Depression OCD (Obsessive Compulsive Disorder), Generalized Anxiety Disorder, Panic Disorder |
||
Geographies covered: |
North America: U.S., Canada, Mexico Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Africa: South Africa, North Africa, and Africa Middle East: GCC, Israel, and Rest of Middle East Latin America: Brazil, Argentina, Rest of Latin America |
||
Companies covered: |
Johnson and Johnson Company (U.S), Merck Pharmaceutical Company (U.S), GlaxoSmithKline Pharmaceutical Company (U.K), Sanofi Pharmaceutical Company (France), Pfizer Pharmaceutical Company (U.S), AstraZeneca Pharmaceutical Industry Company (U.K), Alkermes Biotechnology Company (Ireland), among others |
The Global Depression Drugs Market Has Been Segmented Into:
The Global Depression Drugs Market – By Drug Type:
The Global Depression Drugs Market – By Distributional Channel:
The Global Depression Drugs Market – By Mental Disorder Type:
The Global Depression Drugs Market – By Regions:
North America
Europe
Asia-Pacific
Latin America, Middle East & Africa (LAMEA)
Customization options available to meet your custom research requirements :